Outlook Therapeutics grants options to CFO
Outlook Therapeutics, Inc. reported that Chief Financial Officer Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026 under its 2024 Equity Incentive Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. reported that Chief Financial Officer Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026 under its 2024 Equity Incentive Plan. Each option covers one share of common stock at an exercise price of 1.4304 per share, vests in full on July 21, 2027, and expires on July 21, 2036, conditional on his continued service.
Insider Trade Summary
Grant/Award: 210,078 shares
Grant/Award
1 txn
Insider
KENYON LAWRENCE A
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 210,078 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 210,078 contracts (Direct)
Footnotes (1)
- F1. The option was granted to Mr. Kenyon on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Kenyon's continuing service with the Issuer through such vesting date.
Key Figures
Stock options granted: 210078.0000 options
Exercise price: 1.4304 per share
Underlying common shares: 210078.0000 shares
+3 more
6 metrics
Stock options granted
210078.0000 options
Grant to CFO Lawrence A. Kenyon on July 21, 2026
Exercise price
1.4304 per share
Exercise price for the granted stock options
Underlying common shares
210078.0000 shares
Common stock issuable upon exercise of granted options
Vesting date
July 21, 2027
Date options vest and become exercisable in full
Expiration date
July 21, 2036
Expiry of options if not exercised
Post-grant option holdings
210078.0000 options
Total derivative securities owned after the reported grant
Key Terms
Stock Option (Right to Buy), Equity Incentive Plan, exercise price, vesting
4 terms
Stock Option (Right to Buy) financial
"Reported security titled "Stock Option (Right to Buy)" for 210,078 shares"
Equity Incentive Plan financial
"The option was granted pursuant to the Issuer's 2024 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
exercise price financial
"Each option has a conversion or exercise price of 1.4304 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests and becomes exercisable in full on July 21, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Outlook Therapeutics (OTLK) report for its CFO?
Outlook Therapeutics reported that CFO Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026. The options are a compensation award under the company’s 2024 Equity Incentive Plan.
How many stock options did the Outlook Therapeutics (OTLK) CFO receive?
The CFO received 210,078 stock options, each for one share of common stock. Following this grant, his reported derivative holdings related to this award total 210,078 options.
What is the exercise price of the Outlook Therapeutics (OTLK) CFO’s new options?
The granted options carry an exercise price of 1.4304 per share. This is the price at which the CFO can purchase Outlook Therapeutics common stock once the options vest and are exercised.
When do the CFO’s new Outlook Therapeutics (OTLK) options vest and expire?
The options vest and become fully exercisable on July 21, 2027, subject to the CFO’s continued service. They have an expiration date of July 21, 2036 if not exercised earlier.
Under what plan were the Outlook Therapeutics (OTLK) CFO’s options granted?
The options were granted under the company’s 2024 Equity Incentive Plan using its standard stock option agreement. This plan governs the terms, including vesting and expiration conditions for the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates